Hologen is paying MeiraGTx $200 million upfront and committing $230 million to fund Hologen Neuro AI and a Parkinson's disease gene therapy.

The agency advises patients to confirm that any cell, gene, or tissue therapy they receive is approved by a regulator or authorized for use in a clinical trial.

By correcting for ancestral bias in publicly available datasets, PhyloFrame produces better outcomes predictions for under-sampled populations.

Coeptis previously held limited co-development rights to GEAR. In conjunction with the new license agreement, Coeptis has formed a majority-owned subsidiary, called GEAR Therapeutics, to evaluate GEAR ...